Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C.
Figlerowicz
Magdalena
M
Department of Infectious Diseases, University of Medical Sciences, Szpitalna 27/33, 60-572 Poznan, Poland. mfiglerowicz@sk5.usoms.poznan.pl
Sluzewski
Wojciech
W
Kowala-Piaskowska
Arleta
A
Mozer-Lisewska
Iwona
I
D000293:Adolescent; D000410:Alanine Transaminase / Q000378:metabolism; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D012367:RNA, Viral / Q000097:blood; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D000998:Antiviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral; D012254:Ribavirin; D000410:Alanine Transaminase